Chongqing
Disclosure information not submitted.
2199 - First-Line Tyrosine Kinase Inhibitor with or without Upfront Stereotactic Body Radiotherapy for Residual Primary Lesions in Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Sunday, September 29, 20242:45 PM – 4:15 PM ET
